3/2
07:42 am
trvi
Trevi Therapeutics to Participate in Upcoming March Conferences [Yahoo! Finance]
Medium
Report
Trevi Therapeutics to Participate in Upcoming March Conferences [Yahoo! Finance]
3/2
07:30 am
trvi
Trevi Therapeutics to Participate in Upcoming March Conferences
Medium
Report
Trevi Therapeutics to Participate in Upcoming March Conferences
2/28
08:32 pm
trvi
Assessing Trevi Therapeutics (TRVI) Valuation After Strong Long Term Returns And A Rich Price To Book Ratio [Yahoo! Finance]
Medium
Report
Assessing Trevi Therapeutics (TRVI) Valuation After Strong Long Term Returns And A Rich Price To Book Ratio [Yahoo! Finance]
2/17
07:55 am
trvi
Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Low
Report
Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/17
07:30 am
trvi
Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Low
Report
Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
1/22
12:30 pm
trvi
Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)
Low
Report
Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)
1/11
07:40 pm
trvi
Is Trevi Therapeutics (TRVI) Building a Multi-Indication Moat With Its Nalbuphine ER Cough Strategy? [Yahoo! Finance]
Low
Report
Is Trevi Therapeutics (TRVI) Building a Multi-Indication Moat With Its Nalbuphine ER Cough Strategy? [Yahoo! Finance]
1/11
06:37 pm
trvi
Trevi Therapeutics (TRVI) Valuation Check After FDA End Of Phase 2 Update And Renewed Analyst Optimism [Yahoo! Finance]
Low
Report
Trevi Therapeutics (TRVI) Valuation Check After FDA End Of Phase 2 Update And Renewed Analyst Optimism [Yahoo! Finance]
1/9
08:02 am
trvi
Trevi Therapeutics (NASDAQ:TRVI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Low
Report
Trevi Therapeutics (NASDAQ:TRVI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
1/8
08:23 am
trvi
Trevi Therapeutics (NASDAQ:TRVI) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $19.00 price target on the stock.
Low
Report
Trevi Therapeutics (NASDAQ:TRVI) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $19.00 price target on the stock.
1/8
07:30 am
trvi
Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference
Low
Report
Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference
12/23
01:23 pm
trvi
MarketBeat's Top 5 Rated Small-Cap Stocks [Yahoo! Finance]
Low
Report
MarketBeat's Top 5 Rated Small-Cap Stocks [Yahoo! Finance]
12/21
07:42 am
trvi
Trevi Therapeutics (TRVI) Targets Next Phase of Growth with Leadership Change [Yahoo! Finance]
Medium
Report
Trevi Therapeutics (TRVI) Targets Next Phase of Growth with Leadership Change [Yahoo! Finance]
12/19
10:04 am
trvi
Trevi Therapeutics (NASDAQ:TRVI) was given a new $18.00 price target on by analysts at Stifel Nicolaus.
Medium
Report
Trevi Therapeutics (NASDAQ:TRVI) was given a new $18.00 price target on by analysts at Stifel Nicolaus.